Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.

By BioPharma Dive staff • Aug. 14, 2026

Biotech initiatives pick up as more regions race to become hubs

New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t determine where pharma builds next.

By Alexandra Pecci • Aug. 14, 2026

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

New Taiho, Cullinan data heats up lung cancer drug battle

The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.

By Jonathan Gardner • Aug. 13, 2026

Psychedelics developer Definium scores more positive data for LSD pill

Results from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.

By Jacob Bell • Aug. 12, 2026

Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines

Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels not seen since 2023.

By BioPharma Dive staff • Aug. 12, 2026

Boulevard starts up with $65M to pursue targeted autoimmune drugs

Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.

By Gwendolyn Wu • Aug. 12, 2026

Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs

Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.

By Jonathan Gardner • Aug. 11, 2026

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.

By Gwendolyn Wu • Aug. 11, 2026

Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease

The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.

By Delilah Alvarado • Aug. 11, 2026

Vaderis hauls in $152M to test an AKT-targeting drug

The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.

By Gwendolyn Wu • Aug. 11, 2026

Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.

By Jonathan Gardner • Aug. 10, 2026

Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses

The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years. 

By Gwendolyn Wu • Aug. 10, 2026

‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit

Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.

By BioPharma Dive staff • Aug. 7, 2026

Latigo IPO raises nearly $350M for pain drug development

The company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its offering also adds to a recent and significant uptick in large biotech IPOs.

By Jacob Bell • Aug. 7, 2026

Replimune rebounds to win FDA approval of melanoma drug

The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.

By Jonathan Gardner • Aug. 6, 2026

Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M

Alkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve ever seen.” 

By Ben Fidler • Aug. 6, 2026

With $263M, LifeMine unearths a new drug for organ transplants

Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplanted organs. 

By Gwendolyn Wu • Aug. 6, 2026

Cardiac drug developer Braveheart banks more than $382M in IPO

Braveheart’s offering was the largest among four biotech IPOs that collectively raised more than $1 billion from public investors last week.

By Gwendolyn Wu • Updated Aug. 6, 2026

Attovia adds to biotech IPO momentum with $289M offering

The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen during the sector’s pandemic peak, according to BioPharma Dive data.

By Jonathan Gardner • Aug. 5, 2026

Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch

Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.

By Delilah Alvarado , Ben Fidler • Aug. 5, 2026

A COPD drug from China draws $115M in venture funding

Expedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.

By Gwendolyn Wu • Aug. 5, 2026

Vertex’s biggest overhang: a rival 50 times smaller

Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics "looms large" over Vertex.

By Jacob Bell • Aug. 4, 2026

J&J pharma leader to retire; Krystal slumps on gene therapy miss

Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.

By BioPharma Dive staff • Aug. 4, 2026

BioNTech taps Sobi executive Oelkers as its next CEO

Guido Oelkers will guide BioNTech’s ongoing transition into an oncology-focused biotech, while co-founder and longtime leader Ugur Sahin prepares to join a fledgling mRNA startup.

By Delilah Alvarado • Aug. 3, 2026

Supernus, Indivior merge to beef up brain drug portfolio

The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Parkinson's.

By Jonathan Gardner • Aug. 3, 2026